At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Jul 13, 2026 at 20:35 ET
Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. This milestone de-risks the trial timeline, but results are not expected until mid-2027, leaving significant binary risk. The stock may see a modest positive reaction, but the lack of efficacy data limits the near-term catalyst.
- Enrollment target of at least 300 patients achieved in MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
- Top-line results expected in mid-CY2027 after the last patient completes 12 months follow-up.
- Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, providing eligibility for priority review and rolling BLA review.
- Company estimates peak year revenue potential of >$10 billion with single-digit market penetration, though this is forward-looking and not supported by current data.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access